BD’s TriPath Imaging Buyout Would Integrate Cancer Diagnostics Partner
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson will gain TriPath Imaging's SurePath liquid-based Pap test and fledgling molecular oncology diagnostics business should its $350 mil. acquisition offer be accepted
You may also be interested in...
BD Diagnostics Revenue Up 3% In Fiscal First Quarter, But Medical Sales Fall
BD's diagnostics revenue rose 3.3% to $540.1 million in the firm's fiscal first quarter, aided by sales of safety-engineered products, cancer tests and infectious disease assays, the firm reported Jan. 28
BD Diagnostics Revenue Up 3% In Fiscal First Quarter, But Medical Sales Fall
BD's diagnostics revenue rose 3.3% to $540.1 million in the firm's fiscal first quarter, aided by sales of safety-engineered products, cancer tests and infectious disease assays, the firm reported Jan. 28
Earnings Calls In Brief
Consumers still spending for Allergan aesthetic treatments: Aesthetic product sales pushed Allergan's device revenues ahead 70% in the fourth quarter compared to a year ago, to $216.9 million, or 49% on a pro-forma local currency basis after accounting for acquisitions, the firm reports Jan. 30. Sales of facial dermal fillers, including Juvederm, more than doubled to $61 million while breast implant sales increased 38% to $81 million and sales of obesity intervention products, including the Lap-Band system, ballooned 50% to $74 million. Overall, the diversified device and drug maker reported fourth quarter sales of $1.07 billion, up 31.7% from the same quarter a year ago. "While we obviously cannot fully predict future economic trends and their impact on our markets, up to today we have not detected any impact on our sales of any slowdown in consumer spending in the United States or other major markets in the world," CEO David Pyott noted. For 2008, the company forecasts device sales of $870 million-$955 million, up 12%-23% from $774 million in 2007, including facial aesthetics sales of $225 million-$255 million; breast implant sales of $330 million-$350 million; and obesity intervention sales of $315 million-$350 million